Get the Daily Brief
Latest Biotech News
Obesity drug pipeline: Boehringer’s survodutide posts Phase 3 weight-loss readout
Boehringer Ingelheim disclosed Phase 3 results for survodutide, reporting 16.6% mean weight loss after about a year of treatment, using a dual-agonist approach that targets GLP-1 and glucagon...
Oral in vivo gene editing: Intellia tees up FDA filing after Phase 3 hereditary angioedema win
Intellia reported Phase 3 success for its in vivo CRISPR medicine lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), meeting the primary endpoint by reducing swelling attack rates 87%...
In vivo CRISPR momentum: Intellia files with FDA after lonvo-z hits Phase 3 HAE endpoint
Intellia said its lonvo-z CRISPR therapy achieved the primary endpoint in a Phase 3 trial for hereditary angioedema and has now moved toward an FDA submission. The biotech reported an 87%...
Big Pharma M&A: Eli Lilly buys Ajax Therapeutics for up to $2.3B to bolster JAK franchise
Eli Lilly announced it will acquire Ajax Therapeutics for up to $2.3 billion in cash, adding next-generation JAK biology for myeloproliferative neoplasms. The deal gives Lilly access to AJ1-11095,...
Genome engineering platform: Gladstone’s retron recombineering extends efficient editing beyond E. coli
Gladstone Institutes researchers reported a retron-based genome editing approach that works across diverse bacterial species beyond E. coli. The study, published in Nature Biotechnology, describes...
Immuno-oncology targets: AACR analyses surface 176 proposed new cancer targets
A BioCentury analysis of the nearly 7,000 abstracts at AACR 2026 identified 176 new oncology targets proposed for future therapies. The review emphasized immuno-oncology themes, including...
Autoimmune dermatology: Oruka’s IL-23 antibody posts strong Phase 2 psoriasis clearance rates
Oruka Therapeutics reported Phase 2a results for its long-acting IL-23 monoclonal antibody ORKA-001 in plaque psoriasis, with 40 of 63 patients achieving PASI 100 at 16 weeks and 83% reaching PASI...
Atrial fibrillation med-tech race: PFA data keep positioning ahead in Heart Rhythm update cycle
Pulmonary vein ablation competition intensified as new pulsed field ablation (PFA) data presented at Heart Rhythm 2026 continued to show clinical benefits and technology differentiation for...
Coronary artery disease biomarkers: PlaqueTec raises $5M to build intracoronary protein database
PlaqueTec raised $5 million in an oversubscribed financing round led entirely by existing investors, funding continued work on its BIOPATTERN clinical trial for coronary artery disease biomarkers....
Regulatory and access: New data show QC gaps after CDC testing pause – Wadsworth Center steps in
The New York State Department of Health’s Wadsworth Center said it is filling laboratory testing gaps triggered by the US Centers for Disease Control and Prevention’s pause on testing for multiple...
In vivo CRISPR gene editing moves to an FDA filing pathway
Intellia Therapeutics reported Phase 3 success for lonvo-z (lonvoguran ziclumeran) in hereditary angioedema (HAE), cutting swelling attack rates by 87% versus placebo over six months. In the...
Big Pharma doubles down on next-generation JAK inhibitors through Ajax acquisition
Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, adding a clinical-stage JAK2 inhibitor program for myeloproliferative neoplasms. Ajax’s lead asset, AJ1-11095, is a...
Regenerative oncology: a new approach targets senescent-cell survival machinery
Researchers from MRC Laboratory of Medical Sciences and Imperial College London identified a senescence vulnerability tied to GPX4-dependent ferroptosis. In models of melanoma, prostate and...
Checkpoint and cell-therapy fusion: IL-2 delivery strategy boosts solid tumor responses
Anwita Biosciences and collaborators designed an immune-engaging approach that fuses a checkpoint inhibitor concept with cytokine delivery to address two solid-tumor constraints: inhibitory...
Momentum in psoriasis therapeutics: Oruka’s long-acting IL-23 antibody shows strong Phase 2 clearance rates
Oruka Therapeutics reported Phase 2 psoriasis data for ORKA-001, a half-life-extended IL-23 monoclonal antibody, with 40 of 63 treated patients (63.5%) achieving PASI 100 at 16 weeks versus 1 of...
Atherosclerosis prevention biology surfaces: vessels use a natural defense mechanism
Baylor College of Medicine researchers reported in PNAS that blood vessels possess a self-protective defense mechanism that slows or prevents the progression of atherosclerosis. The study...
Cardiometabolic drug trial: Boehringer’s dual agonist posts 16.6% weight loss in Phase 3
Boehringer Ingelheim reported Phase 3 results for a glucagon-targeted dual agonist showing 16.6% weight loss, while stopping short of the performance seen with established therapies. The company...
Diagnostics and tools: IQ-driven spatial proteomics service expands CRO capabilities
Nucleai and spatial proteomics-focused CRO Sirona Dx partnered to deliver AI-driven spatial proteomics services for biopharma. Sirona Dx will lead assay design, development and validation to...
Cardiology trial disrupts treatment sequence in advanced atrial fibrillation
A randomized international trial led by the University of British Columbia found that starting treatment with a minimally invasive approach for advanced atrial fibrillation reduced the need for...
New UK biotech funding signal: Q1 2026 VC investment rebounds
UK biotech venture capital investment rebounded in Q1 2026, with total sector investment reaching £552 million (about $748 million), according to a report cited from the BioIndustry Association....